A novel combination therapy with first-in-human roots at the University of Colorado Anschutz delivered effective and durable responses in patients with advanced, muscle-invasive bladder cancer (MIBC), according to a new study in the New England Journal of Medicine. The statistically significant results of the multi-site, phase-3 clinical trial signal a potential new standard of care for this dangerous stage of bladder cancer.